Diabeloop expands its presence in Germany
Diabeloop GmbH subsidiary is now active in Siegen
Diabeloop SA, a pioneer in therapeutic artificial intelligence, now operates on the German market under the name Diabeloop GmbH. The Grenoble-based company is thus taking a further step towards entering the European market. Diabeloop GmbH aims to bring its technologies for automated and personalized management of Type 1 diabetes in Germany as soon as possible.
After the French pre-launch of the DBLG1, preparations for entry into the German market are underway. As soon as it is possible, people living with Type 1 diabetes in Germany should also be able to automate and personalize the management of their condition thanks to Diabeloop’s system. This self-learning algorithm is made to relieve patients of the many therapeutic decisions they have to make every day.
In order to be able to optimally animate its presence on the German market, Diabeloop is currently expanding its team under the direction of Christian Krey, and now operates in Germany under the name Diabeloop GmbH. With the opening of this subsidiary in Siegen, the developments related to the market entry are progressing. At the same time, very positive discussions on reimbursement possibilities are currently being held with the major public and private health insurances.
Moreover, the team surrounding Christian Krey is working with renowned experts to set up an Advisory Board in Germany. This Advisory Board, which will be composed of experts in diabetes, clinics and medical practices as well as psychologists, will be actively involved in the study programs intended by Diabeloop.
“We are in close contact with renowned experts in all of Germany. We are very happy that our work in the new German subsidiary will be able to benefit from their valuable experiences as well as from the expertise of the Advisory Board that we are currently setting up”, states Christian Krey.
“Innovative therapies are particularly crucial in the self-management of diabetes. Diabeloop’s DBLG1 is thus forward-looking in that it allows an autonomous management of diabetes and that patients living with Type 1 diabetes, according to the SP7 study, find themselves in range for an additional 2 hours per day. Furthermore, data protection is implemented in an exemplary manner; the patient will retain full authority over the decision to share his data or not”, adds Dr. Andreas Lueg, specialist in internal medicine and diabetes at the L1 Diabetes Centre in Hamelin.
Some of those studies will be conducted on the key market that is Germany. Study centres and clinics are expected to take part in these international studies. A specific study on Type 1 diabetes in adolescents is to be launched this year.
“We are looking forward to the next steps in Germany. Our goal is to provide the DBLG1, personalized self-management system for Type 1 diabetes, in Germany soon. Our system relieves people with this condition of the heaven mental load associated with having to make over thirty therapeutic decisions in 24 hours. They should all be able to live without interruption!”, concludes Marc Julien, CEO of Diabeloop.
Diabeloop’s mission: to relieve people living with Type 1 diabetes from dozens of therapeutic decisions and reduce their heavy mental burden. Initially conceived from a medical research project, Diabeloop was created in 2015 by Dr. Guillaume Charpentier, now Chief Medical Officer, and Erik Huneker who have co-managed the company with Marc Julien since 2016. This complementary management team works with experienced partners, CEA-Leti (a research laboratory) and CERITD (a French research team of diabetologists). In November 2018, the DBLG1 System, Diabeloop’s first medical device for automated diabetes management, obtained CE marking.
A second round of financing of 31 million euros concluded in November 2019 to speed up the international commercial rollout of the DBLG1 iController and support an ambitious R&D program.
Today, Diabeloop gathers the personality, the passion and the skills of 70 talented individuals who work hard to improve the quality of life for every person living with Type 1 diabetes.
Press contact :
Diabeloop – Stéphanie JEGU – email@example.com